Panelists discuss how clinicians should approach OSA evaluation by clearly defining what brought the patient in, establishing that sleep apnea encompasses more than just breathing issues, taking a comprehensive snapshot of current symptoms, and framing the sleep study as the beginning rather than the end of the treatment process.
The nurse practitioner in the Center for Movement Disorders & Neurorestoration at the University of Florida discussed clinical experiences with deep brain stimulation for atypical MS tremor and PD. [WATCH TIME: 5 minutes]
The director of the Movement Disorders Clinic at Houston Methodist Hospital outlined a stepwise approach for identifying, managing, and treating hallucinations in patients with Parkinson disease. [WATCH TIME: 3 minutes]
The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about how to ensure a smooth transition from pediatric to adult epilepsy care for university students. [WATCH TIME: 4 minutes]
Neurology News Network. for the week ending August 30, 2025. [WATCH TIME: 4 minutes]
The director of the Norman Fixel Institute for Neurological Diseases at UF Health talked about prevention, understanding disease mechanisms, and creating a patient-centered care model in Parkinson disease. [WATCH TIME: 5 minutes]
The head of the neurology department at the Vall d’Hebron University Hospital shared thoughts and perspectives on significance of fremanezumab’s recently expanded approval, calling it a long-awaited breakthrough for treating pediatric migraine. [WATCH TIME: 3 minutes]
Panelists discuss how promising disease-modifying therapies including antisense oligonucleotide and viral vector treatments are currently in clinical trials and target the underlying SCN1A gene defect, rather than just treating seizure symptoms, showing encouraging results in seizure reduction and nonseizure outcomes such as language development, though these therapies will likely complement rather than replace existing medications when they become available in several years.
The neurophysiologist at Allegheny Health Network shared his clinical experience with tofersen in patients with SOD-1 ALS, while emphasizing the critical role of accessible genetic testing for patient identification. [WATCH TIME: 3 minutes]
Panelists discuss how despite newer medications such as cannabidiol, stiripentol, and fenfluramine being available for several years and recommended as first-line therapies, claims data reveal that only 7% to 25% of patients with newly diagnosed Dravet syndrome receive these treatments, with many clinicians still defaulting to older, less effective medications due to lack of practical guidance on dosing and titration protocols for the newer therapies.
The vice chair of education for the department of neurology at Mass General outlined her AUPN 2025 session on supporting clinician educators through recognition, career development, and institutional frameworks for advancement. [WATCH TIME: 4 minutes]
An expert discusses how treatment for the 13-year-old patient should optimize standard care with cardiac and pulmonary monitoring while considering newer therapies like givinostat and casimersen, plus exploring research trials for gene transfer and muscle health approaches.
An expert discusses how genetic therapies like exon skipping and gene transfer aim to restore dystrophin function but face challenges in delivering complete protein restoration and achieving equivalent effectiveness across skeletal, cardiac, and pulmonary muscles.
The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]
The neurologist at Maimonides Medical Center and SUNY Downstate shared how interactive simulations give neurology trainees the chance to practice skills, gain feedback, and move beyond passive learning. [WATCH TIME: 3 minutes]
Panelists discuss their excitement about future treatments, such as orexin agonists and nighttime approaches to sleep-wake balance, but express concern that insurance barriers and approval difficulties may prevent patients from accessing even the most effective new medications.
Panelists discuss how solriamfetol distinguishes itself from existing wake-promoting medications through its dual dopamine-norepinephrine reuptake inhibition, with patients reporting they "feel better" on it beyond just improved wakefulness, while emphasizing careful dose titration to minimize adverse effects like anxiety and cardiovascular changes.
At the 2025 ATMRD Congress, a patient advocate living with Parkinson disease emphasized the importance of amplifying patient voices at educational conferences for movement disorders. [WATCH TIME: 5 minutes]
Neurology News Network. for the week ending August 23, 2025. [WATCH TIME: 4 minutes]
The professor and chair of neuroscience at UT Southwestern Medical Center discussed how circadian clock genes regulate cellular metabolism and potentially influence headache. [WATCH TIME: 6 minutes]
The headache neurologist at the Barrow Neurological Institute talked about an international expert panel that established agreed-upon definitions for refractory and resistant migraine. [WATCH TIME: 4 minutes]
At AHS 2025, the associate clinic director at the UC San Diego talked about the cautious use of cannabinoids in migraine and the importance of standard therapies before cannabinoids. [WATCH TIME: 3 minutes]
Panelists discuss how newer medications such as stiripentol have become preferred over traditional options such as valproate for younger patients, emphasizing the importance of assessing treatment effectiveness within 6 to 8 weeks rather than accepting "pretty good" seizure control, and encouraging frequent communication with families to optimize therapy and pursue meaningful seizure reduction rather than settling for partial improvements.
The director of the Brotman Facial Pain Clinic at the University of Maryland talked about emerging preclinical evidence supporting adenosine A3 receptor activation for post-traumatic trigeminal neuropathic pain. [WATCH TIME: 5 minutes]
Panelists discuss how treatment selection for Dravet syndrome requires individualized approaches based on seizure types and patient characteristics, emphasizing the importance of striving for seizure freedom, avoiding contraindicated sodium channel medications, utilizing synergistic drug combinations when appropriate, and simplifying medication regimens to twice-daily dosing with clear timing cues to improve family adherence to complex treatment plans.
The chief scientific officer at Alzheon talked about a symposium on the role of amyloid-beta oligomers in AD and phase 3 clinical data of valiltramiprosate presented at AAIC 2025. [WATCH TIME: 5 minutes]
The physician assistant specializing in Parkinson disease talked about how comorbidities and patient preference guide clinical decisions in prescribing on-demand therapies for Parkinson disease. [WATCH TIME: 5 minutes]
The CEO and cofounder of LSVT Global highlighted the importance of clinicians referring their patients with Parkinson disease early to evidence-based physical therapies, occupational therapies, and speech therapies. [WATCH TIME: 5 minutes]
The Harold I. Nemuth Chair in Neurological Disorders at Virginia Commonwealth University provided hypothetical insights on potential stroke-related avenues for GLP-1 RAs to treat following positive data in idiopathic intracranial hypertension. [WATCH TIME: 4 minutes]
An expert discusses how a 13-year-old boy with Duchenne muscular dystrophy faces the challenging transition to complete loss of ambulation, emphasizing the importance of gradual introduction of assistive devices and psychological support during this developmentally difficult period.
